NASDAQ: TCRXTscan Therapeutics Inc Stock Ownership - Who owns Tscan Therapeutics?
Insider buying vs selling
Have Tscan Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner | 2025-12-23 | 6,232 | $0.90 | $5.60kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-12-22 | 75,500 | $0.90 | $67.95kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-12-19 | 80,069 | $0.90 | $71.98kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-05-20 | 1,200,000 | $1.20 | $1.44MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-05-19 | 1,388,794 | $1.20 | $1.67MBuy |
TCRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when TCRX insiders and whales buy or sell their stock.
TCRX Shareholders
What type of owners hold Tscan Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 14.13% | 8,019,148 | $9.06M | Insider |
| Lynx1 Capital Management LP | 13.85% | 7,857,347 | $8.88M | Institution |
| Bvf Inc | 9.21% | 5,226,074 | $5.91M | Institution |
| Ecor1 Capital LLC | 8.81% | 5,000,000 | $5.65M | Insider |
| Baker Bros Advisors LP | 4.91% | 2,784,792 | $3.15M | Institution |
| Baker Bros Advisors LP | 4.46% | 2,528,583 | $2.86M | Insider |
| Blackrock Inc | 4.20% | 2,382,764 | $2.69M | Institution |
| Vanguard Group Inc | 4.08% | 2,317,916 | $2.62M | Institution |
| Propel Bio Management LLC | 3.41% | 1,932,304 | $2.18M | Institution |
| Aberdeen Group PLC | 2.39% | 1,354,820 | $1.53M | Institution |
TCRX vs Biotech Stocks
Tscan Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.